Barbara Tong

2.0k total citations · 1 hit paper
15 papers, 1.0k citations indexed

About

Barbara Tong is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Barbara Tong has authored 15 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Hematology and 4 papers in Oncology. Recurrent topics in Barbara Tong's work include Hemoglobinopathies and Related Disorders (6 papers), Iron Metabolism and Disorders (4 papers) and HER2/EGFR in Cancer Research (3 papers). Barbara Tong is often cited by papers focused on Hemoglobinopathies and Related Disorders (6 papers), Iron Metabolism and Disorders (4 papers) and HER2/EGFR in Cancer Research (3 papers). Barbara Tong collaborates with scholars based in United States, United Kingdom and Lebanon. Barbara Tong's co-authors include Yu-Waye Chu, Sara A. Hurvitz, Kert Viele, J. Vinholes, Edith A. Perez, Luc Dirix, Vivian Ng, Judit Kocsis, Janice Lu and Chunyan Song and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Barbara Tong

15 papers receiving 1000 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration

2018 264 citations Frank G. Holz, Srinivas R. Sadda et al. JAMA Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Tong United States	7	555	542	227	208	172	15	1.0k
Maria Wang United States	16	397 0.7×	362 0.7×	621 2.7×	816 3.9×	114 0.7×	42	1.9k
Ruud Clarijs Netherlands	15	299 0.5×	248 0.5×	76 0.3×	282 1.4×	93 0.5×	19	942
Eleonora Rofi Italy	20	148 0.3×	563 1.0×	131 0.6×	621 3.0×	116 0.7×	39	1.4k
Marie‐Paule Sablin France	18	64 0.1×	499 0.9×	73 0.3×	410 2.0×	89 0.5×	50	942
Robin Edwards United States	12	205 0.4×	492 0.9×	19 0.1×	493 2.4×	131 0.8×	25	1.1k
Virginia Picasso Italy	12	29 0.1×	400 0.7×	157 0.7×	314 1.5×	197 1.1×	16	661
Yulia Bronstein United States	10	177 0.3×	644 1.2×	14 0.1×	209 1.0×	71 0.4×	15	903
Jacopo Pigozzo Italy	22	51 0.1×	1.7k 3.1×	176 0.8×	590 2.8×	658 3.8×	56	2.0k
Francesco Merolla Italy	25	88 0.2×	486 0.9×	28 0.1×	845 4.1×	75 0.4×	66	1.3k
Jose Gerard Monzon Canada	17	36 0.1×	773 1.4×	87 0.4×	403 1.9×	175 1.0×	62	1.2k

Countries citing papers authored by Barbara Tong

Since Specialization

Citations

This map shows the geographic impact of Barbara Tong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Tong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Tong more than expected).

Fields of papers citing papers by Barbara Tong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Tong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Tong. The network helps show where Barbara Tong may publish in the future.

Co-authorship network of co-authors of Barbara Tong

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Tong. A scholar is included among the top collaborators of Barbara Tong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Tong. Barbara Tong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Layton, D. Mark, et al.. (2021). RESULTS FROM A PHASE 2 STUDY OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. Hematology Transfusion and Cell Therapy. 43. S28–S28. 1 indexed citations

Layton, D. Mark, Hanny Al‐Samkari, Antonios Kattamis, et al.. (2021). ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. Hematology Transfusion and Cell Therapy. 43. S20–S20. 4 indexed citations

Lehrer‐Graiwer, Joshua, et al.. (2020). Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell disease. Contemporary Clinical Trials. 98. 106161–106161. 4 indexed citations

Howard, Jo, Elliott Vichinsky, Jennifer Knight‐Madden, et al.. (2019). Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study. Blood. 134(Supplement_1). 1020–1020. 5 indexed citations

Ware, Russell E., R. Clark Brown, Mariane de Montalembert, et al.. (2019). Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study. Blood. 134(Supplement_1). 1003–1003. 4 indexed citations

Vichinsky, Elliott, Paul Telfer, Adlette Inati, et al.. (2019). Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study. Blood. 134(Supplement_1). 2313–2313. 6 indexed citations

Pieramici, Dante J., Frank G. Holz, Jeffrey S. Heier, et al.. (2018). Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs). Investigative Ophthalmology & Visual Science. 59(9). 4948–4948. 2 indexed citations

Holz, Frank G., Srinivas R. Sadda, Brandon Busbee, et al.. (2018). Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration. JAMA Ophthalmology. 136(6). 666–666. 264 indexed citations breakdown →

Gong, Qi, et al.. (2014). Analysis of safety data in clinical trials using a recurrent event approach. Pharmaceutical Statistics. 13(2). 136–144. 10 indexed citations

10.

Hurvitz, Sara A., Luc Dirix, Judit Kocsis, et al.. (2013). Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 31(9). 1157–1163. 302 indexed citations

11.

Girish, Sandhya, Manish Gupta, Bei Wang, et al.. (2012). Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology. 69(5). 1229–1240. 198 indexed citations

12.

Hurvitz, Sara A., L. Dirix, Judit Kocsis, et al.. (2011). 5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976). European Journal of Cancer. 47. S330–S330. 46 indexed citations

13.

Gluck, William Larry, Deborah Hurst, Alan R. Yuen, et al.. (2004). Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma. Clinical Cancer Research. 10(7). 2253–2264. 127 indexed citations

14.

Viele, Kert & Barbara Tong. (2002). Modeling with Mixtures of Linear Regressions. Statistics and Computing. 12(4). 315–330. 59 indexed citations

15.

Tong, Barbara & Kert Viele. (2000). Smooth estimates of normal mixtures. Canadian Journal of Statistics. 28(3). 551–562. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact